ESMO关于实体瘤基因组检测结果临床报告的建议
欧洲肿瘤内科学会(ESMO)转化研究与精准医学工作组组织国际专家,经证据回顾、多轮调查和专题讨论达成共识,提出实体瘤临床基因组报告建议。建议报告设首页呈现关键信息,后续附附录,并按患者与样本信息、检测与数据分析特征、样本特异性检测性能与质控、基因组改变及功能注释、临床可操作性评估与潜在治疗指征匹配、主要发现总结六部分结构化呈现。仅报告达成共识的建议,按临床重要性分为A级(维持报告通用标准所必需)和B级(可选但实现理想实践所必需)。
要点
- 基因组报告应以首页呈现关键信息,补充信息置于一个或多个附录中。
- 报告应结构化分为六部分:患者与样本信息、检测与数据分析特征、样本特异性检测性能与质控、基因组改变及功能注释、临床可操作性评估与潜在治疗指征匹配、主要发现总结。
- 建议按临床重要性分为A级(维持报告通用标准所必需)和B级(可选但实现理想实践所必需),仅报告达成共识的建议。
核心结论
- ESMO转化研究与精准医学工作组提出一套建议,旨在结构化基因组报告以增强医生对实体瘤基因组检测结果的理解。
- 开具检测的医生与报告基因组数据的专业人员之间的沟通是减少不确定性并优化基因组检测在患者诊疗中影响的关键。
研究设计与样本
- ESMO转化研究与精准医学工作组组织国际专家组,经证据回顾、多轮调查和专题讨论达成共识,提出实体瘤临床基因组报告建议。
- 仅报告达成共识的建议,建议按临床重要性分为A级(维持报告通用标准所必需)和B级(可选但实现理想实践所必需)。
主要发现
- 基因组报告应以首页呈现关键信息,后续以一个或多个附录呈现补充信息。
关键数值与推荐
- 报告应结构化分为六部分:患者与样本信息;检测与数据分析特征;样本特异性检测性能与质控;基因组改变及其功能注释;临床可操作性评估与潜在治疗指征匹配;主要发现总结。
- 针对上述每一部分提出了具体建议。
- 建议分为A级(维持报告通用标准所必需)和B级(可选但实现理想实践所必需)。
临床怎么用
- 基因组报告应按建议的六部分结构组织,以首页呈现关键信息、附录呈现补充信息。
- 开具检测的医生与报告基因组数据的专业人员之间应进行沟通,以最大限度减少不确定性并优化基因组检测在患者诊疗中的影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic tumour profiling has a crucial role in the management of patients with solid cancers, as it helps selecting and prioritising therapeutic interventions based on prognostic and predictive biomarkers, as well as identifying markers of hereditary cancers. Harmonised approaches to interpret the results of genomic testing are needed to support physicians in their decision making, prevent inequalities in precision medicine and maximise patient benefit from available cancer management options. METHODS: The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group assembled a group of international experts to propose recommendations for preparing clinical genomic reports for solid cancers. These recommendations aim to foster best practices in integrating genomic testing within clinical settings. After review of available evidence, several rounds of surveys and focused discussions were conducted to reach consensus on the recommendation statements. Only consensus recommendations were reported. Recommendation statements were graded in two tiers based on their clinical importance: level A (required to maintain common standards in reporting) and level B (optional but necessary to achieve ideal practice). RESULTS: Genomics reports should present key information in a front page(s) followed by supplementary information in one or more appendices. Reports should be structured into sections: (i) patient and sample details; (ii) assay and data analysis characteristics; (iii) sample-specific assay performance and quality control; (iv) genomic alterations and their functional annotation; (v) clinical actionability assessment and matching to potential therapy indications; and (vi) summary of the main findings. Specific recommendations to prepare each of these sections are made. CONCLUSIONS: We present a set of recommendations aimed at structuring genomics reports to enhance physician comprehension of genomic profiling results for solid cancers. Communication between ordering physicians and professionals reporting genomic data is key to minimise uncertainties and to optimise the impact of genomic tests in patient care.
引用
- van de Haar J, Roepman P, Andre F, et al. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024. PMID: 39112111. doi:10.1016/j.annonc.2024.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。